uniQure N.V.
QURE
Price:
$5.41
Market Cap:
$263.45M
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzhe...[Read more]
Industry
Biotechnology
IPO Date
2014-02-05
Stock Exchange
NASDAQ
Ticker
QURE
The ROE as of September 2024 (TTM) for uniQure N.V. (QURE) is -158.09%
According to uniQure N.V.’s latest financial reports and current stock price. The company's current ROE is -158.09%. This represents a change of 269.24% compared to the average of -42.82% of the last 4 quarters.
uniQure N.V. (QURE) Historical ROE (quarterly & annually)
How has QURE ROE performed in the past?
The mean historical ROE of uniQure N.V. over the last ten years is -60.76%. The current -158.09% ROE has changed 160.19% with respect to the historical average. Over the past ten years (40 quarters), QURE's ROE was at its highest in in the June 2021 quarter at 63.05%. The ROE was at its lowest in in the June 2017 quarter at -77.95%.
Average
-60.76%
Median
-55.54%
Minimum
-148.54%
Maximum
55.32%
uniQure N.V. (QURE) ROE by Quarter and Year
Discovering the peaks and valleys of uniQure N.V. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 457.68%
Maximum Annual ROE = 55.32%
Minimum Annual Increase = -207.92%
Minimum Annual ROE = -148.54%
| Year | ROE | Change |
|---|---|---|
| 2023 | -148.54% | 457.68% |
| 2022 | -26.64% | -148.15% |
| 2021 | 55.32% | -207.92% |
| 2020 | -51.26% | 29.36% |
| 2019 | -39.62% | -14.57% |
| 2018 | -46.38% | -48.11% |
| 2017 | -89.38% | -22.49% |
| 2016 | -115.31% | 92.75% |
| 2015 | -59.82% | -30.41% |
| 2014 | -85.97% | -82.16% |
uniQure N.V. (QURE) Average ROE
How has QURE ROE performed in the past?
The current ROE of uniQure N.V. (QURE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-39.95%
5-year avg
-42.15%
10-year avg
-60.76%
uniQure N.V. (QURE) ROE vs. Peers
How is QURE’s ROE compared to its peers?
uniQure N.V.’s ROE is greater than Rocket Pharmaceuticals, Inc. (-54.47%), greater than Rhythm Pharmaceuticals, Inc. (-221.66%), greater than Solid Biosciences Inc. (-53.76%), greater than MeiraGTx Holdings plc (-86.28%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Amylyx Pharmaceuticals, Inc. (-46.15%), greater than Acumen Pharmaceuticals, Inc. (-24.63%), greater than Inozyme Pharma, Inc. (-68.93%), less than X4 Pharmaceuticals, Inc. (32.93%), greater than Vaxcyte, Inc. (-30.07%), greater than Larimar Therapeutics, Inc. (-37.84%), greater than Syndax Pharmaceuticals, Inc. (-57.42%), greater than Merus N.V. (-36.33%), greater than Sutro Biopharma, Inc. (-97.19%), greater than Kiniksa Pharmaceuticals, Ltd. (-5.10%), greater than Day One Biopharmaceuticals, Inc. (-122.70%), greater than Structure Therapeutics Inc. (-20.15%), greater than Karuna Therapeutics, Inc. (-30.79%), less than Phathom Pharmaceuticals, Inc. (251.33%), greater than REGENXBIO Inc. (-68.21%), greater than Replimune Group, Inc. (-52.15%), greater than Avidity Biosciences, Inc. (-32.89%), less than Protagonist Therapeutics, Inc. (85.47%),
| Company | ROE | Market cap |
|---|---|---|
| -54.47% | $1.75B | |
| -221.66% | $3.03B | |
| -53.76% | $290.24M | |
| -86.28% | $324.15M | |
| -39.58% | $662.20M | |
| -46.15% | $180.42M | |
| -24.63% | $152.00M | |
| -68.93% | $375.78M | |
| 32.93% | $111.63M | |
| -30.07% | $13.91B | |
| -37.84% | $426.55M | |
| -57.42% | $1.55B | |
| -36.33% | $3.42B | |
| -97.19% | $303.27M | |
| -5.10% | $1.79B | |
| -122.70% | $1.20B | |
| -20.15% | $2.29B | |
| -30.79% | $12.60B | |
| 251.33% | $1.29B | |
| -68.21% | $629.65M | |
| -52.15% | $714.64M | |
| -32.89% | $4.89B | |
| 85.47% | $2.72B |
Build a custom stock screener for uniQure N.V. (QURE) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like uniQure N.V. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
uniQure N.V. (QURE) and other stocks custom spreadsheet templates
The easiest way to analyze a company like uniQure N.V. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is uniQure N.V.'s ROE?
How is the ROE calculated for uniQure N.V. (QURE)?
What is the highest ROE for uniQure N.V. (QURE)?
What is the 3-year average ROE for uniQure N.V. (QURE)?
What is the 5-year average ROE for uniQure N.V. (QURE)?
How does the current ROE for uniQure N.V. (QURE) compare to its historical average?